Table 1. Biological drugs targeting... | Rockefeller University Press

Table 1.

Biological drugs targeting IL-17 or IL-23 approved for psoriasis, PsA, and/or AS

INN	Target	Construct	Labeled indication
Brodalumab	IL-17RA	Fully human mAb	Pso, PsA (Japan only)
Ixekizumab	IL-17A	Humanized mAb	Pso, PsA, AS
Secukinumab	IL-17A	Fully human mAb	Pso, PsA, AS
Guselkumab	IL-23p19	Fully human mAb	Pso
Risankizumab	IL-23p19	Humanized mAb	Pso
Tildrakizumab	IL-23p19	Humanized mAb	Pso
Ustekinumab	IL-12/23p40	Fully human mAb	Pso, PsA

INN	Target	Construct	Labeled indication
Brodalumab	IL-17RA	Fully human mAb	Pso, PsA (Japan only)
Ixekizumab	IL-17A	Humanized mAb	Pso, PsA, AS
Secukinumab	IL-17A	Fully human mAb	Pso, PsA, AS
Guselkumab	IL-23p19	Fully human mAb	Pso
Risankizumab	IL-23p19	Humanized mAb	Pso
Tildrakizumab	IL-23p19	Humanized mAb	Pso
Ustekinumab	IL-12/23p40	Fully human mAb	Pso, PsA

INN, international nonproprietary names; Pso, psoriasis.